Five year of post-marketing safety of teprotumumab: A disproportionality analysis of the FDA adverse event reporting system

A disproportionality analysis of the FDA adverse event reporting system evaluates five years of post-marketing safety data for teprotumumab in thyroid eye disease treatment; hearing-related adverse events are among the findings.